Drug Profile
212 Pb TCMC trastuzumab
Alternative Names: 212 Pb-trastuzumabLatest Information Update: 22 Feb 2018
Price :
$50
*
At a glance
- Originator AREVA Med
- Developer Orano Med; University of Alabama at Birmingham; University of Cincinnati
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Lead radioisotopes; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer metastases; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer-metastases in USA (Intraperitoneal, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV, Injection)
- 01 Jul 2016 Areva completes a phase-I clinical trial in Cancer metastases in USA (Intraperitoneal) (NCT01384253)